key: cord-0889379-zzapvnhs
authors: Sanchez-Pernaute, Olga; Romero-Bueno, Fredeswinda I; O’Callaghan, Albert Selva
title: Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia
date: 2020-04-16
journal: Reumatol Clin
DOI: 10.1016/j.reuma.2020.03.001
sha: f61016cba6e06550905a6895d06d455b90718ffe
doc_id: 889379
cord_uid: zzapvnhs

nan

J o u r n a l P r e -p r o o f Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia ¿Por qué elegir ciclosporina A como primera línea terapéutica para la neumonía causada por COVID-19?

Sir,

The use of immunosuppressive therapies in COVID-19 infection is a recently raised topic which comes to fill an unmet need in the management of the patients 1 . Intriguingly, not only COVID-19 but also SARS and MERS CoVs -all members of the Betacoronavirus genus -associate to an increased risk of respiratory distress syndrome. Already in patients with SARS-CoV, the development of respiratory failure was thought to be the consequence of a vigorous innate immune response, while effectiveness of tocilizumab in COVID-19 infected patients also supports the participation of a cytokine storm in severe phenotypes 1,2 . A factor underlying this explosive response could be the capacity of betacoronaviruses to invade immune-competent cells, particularly macrophages, thereby hijacking the major drivers of innate immune responses.

Nonetheless, targeting pro-inflammatory cytokines is neither the sole nor the first-line immunomodulatory approach in combating the infection. As represented in the figure, complex virus-host cell interactions providing opportunities for therapeutics should be regarded.

Betacoronaviruses replicate and carry out transcriptional activities at the cell cytosol, where the viral genome is detected by RIG-1 like receptor (RLR) helicases. Upon binding of vRNA, RLR activate mitochondrial antiviral proteins (MAVS). These in turn trigger phosphorylation of transcription factors and gene expression of interferons and cytokines, which are pivotal for an effective antiviral response 3 . Mitochondrial function is thus essential for the antiviral defense, while these organelles also need to provide for the increased energetic needs of infected cells. This fact points to mitochondrial failure as the mechanism unchaining severe forms of COVID-19 infection 4 . In brief, infected cells are exposed to an overload of nascent polypeptides, transcriptional machinery and by-products of helicases activation, altogether jeopardizing maintenance of protein folding and triggering cell and mitochondrial stress 5, 6 . In addition, COVID-19 genome polyadelnylation at J o u r n a l P r e -p r o o f the cytosol could waste adenine deposits and challenge mitochondrial permeability transition pore (MPTP). Ultimately, mitochondrial proteostasis collapse would drive caspases activation and irreversible cell damage. According to available literature, calcineurin inhibitors could confer protection from these pathogenic processes. Briefly, these compounds help restore the unfoldedprotein response (UPR) at the cytosol, and may in this way rescue cells from necrosis 7 . In addition, upon targeting cyclophilin D, cyclosporin A inhibits MPTP opening, activates mitochondrial UPR (mtUPR) and prevents mitochondrial failure 8, 9 . Moreover, through this mechanism, cyclosporin A has shown cardioprotective effects in patients with myocardial infarction 10 . Finally, it should be emphasized that cyclosporin A has shown remarkable antiviral activities in a variety of RNA viruses, including the family of betacoronavirus, which employ cyclophilins as chaperones and nuclear factor of activated T cells (NFAT) as a major signaling pathway 12,13 .

On the whole, we suggest that COVID-19 deadly action on host cells including pneumocytes and T lymphocytes, results from their failure to adapt to cell and mitochondrial stress, while dysfunctional macrophages remain as virus reservoir at the target tissue. According to this model, cyclosporin A could confer protection upstream of the cytokine storm in COVID-19 infected patients, a hypothesis which it is planned to be tested in a randomized clinical trial in the coming weeks. 

COVID-19: consider cytokine storm syndromes and immunosuppression

Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study

Intracellular sensing of viral genomes and viral evasion

Mitochondria in innate immune signaling

Modulation of the unfolded protein response by the severe acute respiratory syndrome coronavirus spike protein

The mitochondrial unfolded protein response, a conserved stress response pathway with implications in health and disease

Suppression of NF-B by cyclosporin A and tacrolimus (FK506) via induction of the C/EBP family: implication for unfolded protein response

A novel in vitro CypD-mediated p53 aggregation assay suggests a model for mitochondrial permeability transition by chaperone systems

Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death